Helix BioPharma Commences Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47

Helix BioPharma

announced Monday that clinical site initiation and patient recruitment activities in its Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 have commenced in Poland. "This Phase I/II open-label, non-randomized dose escalation study in patients with non-squamous, non-small cell lung cancer represents the foray into clinical testing for our novel L-DOS47 immunoconjugate therapy," said Prof. Kazimierz Roszkowski-Śliż MD, Ph.D., Helix's European Medical Director and Director and Head of the Clinical Department of the National Tuberculosis and Lung Diseases Research Institute in Warsaw. "The potential benefits to sufferers of this aggressive cancer are significant and I am hopeful for its success."